Raymond James Financial Inc. Makes New Investment in Cellebrite DI Ltd. (NASDAQ:CLBT)

Raymond James Financial Inc. bought a new position in Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund bought 453,700 shares of the company's stock, valued at approximately $9,995,000. Raymond James Financial Inc. owned approximately 0.22% of Cellebrite DI as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also added to or reduced their stakes in CLBT. Quarry LP purchased a new stake in shares of Cellebrite DI in the 3rd quarter valued at $27,000. Advisors Asset Management Inc. grew its stake in shares of Cellebrite DI by 130.5% during the third quarter. Advisors Asset Management Inc. now owns 3,077 shares of the company's stock valued at $52,000 after buying an additional 1,742 shares during the last quarter. R Squared Ltd purchased a new position in shares of Cellebrite DI in the fourth quarter worth about $100,000. Victory Capital Management Inc. bought a new stake in shares of Cellebrite DI in the 4th quarter valued at about $234,000. Finally, Steward Partners Investment Advisory LLC boosted its holdings in Cellebrite DI by 12.1% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 13,590 shares of the company's stock valued at $299,000 after acquiring an additional 1,463 shares during the period. Institutional investors own 45.88% of the company's stock.

Cellebrite DI Price Performance

Cellebrite DI stock traded up $0.73 during mid-day trading on Tuesday, reaching $20.61. 1,508,152 shares of the company traded hands, compared to its average volume of 1,124,953. The firm's 50 day moving average price is $21.08 and its 200 day moving average price is $19.82. Cellebrite DI Ltd. has a 52-week low of $10.25 and a 52-week high of $26.30. The firm has a market capitalization of $4.94 billion, a price-to-earnings ratio of -14.83, a P/E/G ratio of 4.27 and a beta of 1.52.

Remove Ads

Cellebrite DI (NASDAQ:CLBT - Get Free Report) last released its quarterly earnings results on Thursday, February 13th. The company reported $0.07 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.10 by ($0.03). Cellebrite DI had a positive return on equity of 58.70% and a negative net margin of 70.54%. On average, sell-side analysts anticipate that Cellebrite DI Ltd. will post 0.3 EPS for the current year.

Analyst Ratings Changes

CLBT has been the subject of several recent research reports. JPMorgan Chase & Co. boosted their price objective on Cellebrite DI from $24.00 to $28.00 and gave the company an "overweight" rating in a research report on Tuesday, February 11th. Needham & Company LLC reissued a "buy" rating and set a $28.00 price target on shares of Cellebrite DI in a research report on Monday, March 10th. Finally, Lake Street Capital boosted their price objective on shares of Cellebrite DI from $17.00 to $26.00 and gave the company a "buy" rating in a research report on Friday, February 14th. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has an average rating of "Buy" and an average target price of $23.43.

Cellebrite DI Profile

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.